Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma

Nascimento, Catarina; Gameiro, Andreia; Ferreira, João; Correia, Jorge; Ferreira, Fernando

doi:10.3390/cancers13010117

Cited by 17 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to dogs, VEGFR expression has not been evaluated in feline pancreatic carcinoma. However, increased expression of VEGFR has been shown in feline mammary carcinoma [22], along with preliminary evidence of biologic response to toceranib [23], strengthening the argument for toceranib use in both feline and canine pancreatic carcinoma.…”

Section: Discussionmentioning

confidence: 85%

Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma

Musser

Johannes

2021

BMC Vet Res

View full text Add to dashboard Cite

Background Canine pancreatic carcinoma is a rare, aggressive tumour that is often diagnosed late in the course of disease. Effective treatment strategies have been elusive, and overall survival time is short. In humans, treatment with tyrosine kinase inhibitors alone, or in combination with IV gemcitabine, have been moderately effective. As canine and human pancreatic carcinomas share many clinical aspects, strategies that mimic human treatment regimens may confer a better outcome in canine patients. The aim of this study was to assess the role of the veterinary tyrosine kinase inhibitor, toceranib phosphate, in the treatment of cytologically or histologically confirmed canine pancreatic carcinomas. Results Retrospectively, medical records of dogs with confirmed pancreatic carcinoma treated with toceranib were reviewed. Eight dogs were identified that fit the inclusion criteria. Toceranib was well-tolerated by all patients. Six were treated in the gross disease setting. Four had image-based evaluation of clinical benefit (complete response, partial response, or stable disease of > 10 weeks). Of those patients, 1 achieved a partial response, 2 stable disease, and 1 had progressive disease, for an overall clinical benefit rate of 75 %. An additional dog had clinically stable disease that was not confirmed via imaging. The toceranib-specific median overall survival time was 89.5 days (range: 14–506 days). Conclusions Although limited in patient number, this small study suggests that toceranib may have biologic activity in dogs with pancreatic carcinoma. Larger, prospective studies are needed to confirm these preliminary results and define the use of toceranib in the microscopic disease setting.

show abstract

Section: Discussionmentioning

confidence: 85%

Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma

Musser

Johannes

2021

BMC Vet Res

View full text Add to dashboard Cite

show abstract

“…The pathophysiological meaning of this finding is still unclear, but it is known that hormone receptor negative status is associated with more aggressive behavior in malignant lesions [54]. In fact, PR and ER negative statuses are associated with higher microvascular density (MVD) and VEGF expression in HBC and in FMC, which are recognized angiogenic markers, and thus facilitate tumoral growth [55][56][57].…”

Section: Discussionmentioning

confidence: 99%

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions

Soares

Correia

Batista

et al. 2022

Animals

Self Cite

View full text Add to dashboard Cite

Biomarkers are essential in the characterization of neoplastic lesions and aid not only in the classification of the nature of the lesions, but also in the understanding of their ontogeny, development and prognosis. In cats, while mammary carcinomas are increasingly being characterized, information on their benign lesions is still scarce. Indeed, a better characterization of benign lesions could have an important role in unravelling mammary oncogenesis, similar to that in human breast cancer. Thus, in this study, the expression of five markers was analyzed in 47 benign mammary lesions (hyperplasia, dysplasia and benign tumors) collected from 27 queens. Dysplastic and hyperplastic lesions were the most common (41/47, 81.7%). Most of the lesions were classified as ER positive (43/47, 91.5%), PR negative (30/47, 63.8%), fHER2 negative (29/47, 64.4%), CK 5/6 negative (36/47, 76.6%) and with a low Ki-67 index (37/47, 78.7%). Statistical analysis revealed a correlation between younger ages and ER positivity (p = 0.013) and between larger lesions and negative PR status (p = 0.038). These results reinforce the importance of evaluating the expression of the ER status, prevalent in benign lesions, as a putative precursor in cancer progression.

show abstract

“…There was no marked alteration on the expression of TrkB after the treatment of LCH or BO, which indicated that phosphorylation might be involved in its modulation, instead of abundance. VEGFR2 (KDR/Flk-1), with the structures of seven extracellular immunoglobulin homology domains, a transmembrane domain, and a tyrosine kinase domain, is considered to be the most important receptor of VEGF in regulating physiological and pathological angiogeneses ( Takahashi et al, 1999 ; Simons et al, 2016 ; Nascimento et al, 2021 ). Unlike TrkB, the present research proved that the abundances of VEGFR2 and its ligand of VEGF could both be enhanced by BO in DG and SVZ areas, which might be its mechanism involved in BBB remodeling via angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

Synergic Neuroprotection Between Ligusticum Chuanxiong Hort and Borneol Against Ischemic Stroke by Neurogenesis via Modulating Reactive Astrogliosis and Maintaining the Blood–Brain Barrier

Yao

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background:Ligusticum chuanxiong Hort (LCH) is a famous ethnomedicine in Asia known for its excellent output on stroke treatment, and borneol usually acts as an assistant for its reducing permeability of the blood–brain barrier (BBB) after stroke. Although their synergy against brain ischemia was verified in previous studies, the potential mechanism is still unknown.Methods: The research aimed to explore the exact synergic mechanisms between LCH and borneol on neurogenesis within the areas of the dentate gyrus and subventricular zone. After treating middle cerebral artery occlusion rats with LCH (0.1 g/kg) and/or borneol (0.08 g/kg), the neurological severity score, brain infarct ratio, Nissl staining, Evans blue permeability, BBB ultrastructure, and expressions of von Willebrand factor and tight junction–associated proteins were measured. Co-localizations of Nestin+/BrdU+ and doublecortin+/BrdU+, and expressions of neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) were observed under a fluorescence microscope. Moreover, astrocyte polarization markers of complement component 3 and pentraxin 3, and relevant neurotrophins were also detected by immunoblotting.Results: Basically, LCH and borneol had different focuses, although both of them decreased infarct areas, and increased quantity of Nissl bodies and expression of brain-derived neurotrophic factor. LCH increased the neurological severity score, NeuN+ cells, and the ratios of Nestin+/BrdU+ and doublecortin+/BrdU+, and decreased GFAP+ cells and ciliary neurotrophic factor expression. Additionally, it regulated the expressions of complement component 3 and pentraxin 3 to transform astrocyte phenotypes. Borneol improved BBB ultrastructure and increased the expressions of von Willebrand factor, tight junction–associated proteins, vascular endothelial growth factor, and vascular endothelial growth factor receptor 2. Unexpectedly, their combined therapy showed more obvious regulations on the Nissl score, Evans blue permeability, doublecortin+/BrdU+, NeuN+ cells, brain-derived neurotrophic factor, and vascular endothelial growth factor than both of their monotherapies.Conclusions: The results indicated that LCH and borneol were complementary to each other in attenuating brain ischemia by and large. LCH mainly promoted neural stem cell proliferation, neurogenesis, and mature neuron preservation, which was probably related to the transformation of reactive astrocytes from A1 subtype to A2, while borneol preferred to maintain the integrity of the BBB, which provided neurogenesis with a homeostatic environment.

show abstract

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma

Cited by 17 publications

References 42 publications

Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma

Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions

Synergic Neuroprotection Between Ligusticum Chuanxiong Hort and Borneol Against Ischemic Stroke by Neurogenesis via Modulating Reactive Astrogliosis and Maintaining the Blood–Brain Barrier

Contact Info

Product

Resources

About